A previous study showed that DCs in IMQ-treated skin mainly produce IL-1β (52); the study also showed that the IL-1β–IL-1R signaling pathway contributes to skin inflammation and psoriasis pathogenesis. This evidence concerns the gene IL1B and dermatitis.